Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.…
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
Metagenomi Therapeutics (NASDAQ: MGX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 107 employees.
The shares were at 0.5650 USD on 20 November 2026, down 73.8% over 52 weeks. Its 52-week range is 0.5621 USD to 2.275 USD, and it trades at the bottom of that range.
Its market capitalisation is 21.36M USD.
Metagenomi Therapeutics reports return on equity of -55.4% and revenue down 74.8% year over year.
It holds more cash than debt, a net cash position of 65.46M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.